{
    "body": "What is the indication for isradipine?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/8213473", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10728516", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8963604", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2150641", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15257873", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8466736", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7848351", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7918132", 
        "http://www.ncbi.nlm.nih.gov/pubmed/14727944", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7738211", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7789292", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2523644", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2523646", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7921533", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7946181", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12215829", 
        "http://www.ncbi.nlm.nih.gov/pubmed/9544865", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2137344", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11172743", 
        "http://www.ncbi.nlm.nih.gov/pubmed/8205296", 
        "http://www.ncbi.nlm.nih.gov/pubmed/2949585", 
        "http://www.ncbi.nlm.nih.gov/pubmed/1363224", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7621840", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10854683", 
        "http://www.ncbi.nlm.nih.gov/pubmed/7955262"
    ], 
    "ideal_answer": [
        "Isradipine is safe and effective when administered long-term in the treatment of hypertensive patients", 
        "The calcium antagonist isradipine is used for hypertensive therapy."
    ], 
    "exact_answer": [
        "Hypertension"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017275", 
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006973", 
        "http://www.biosemantics.org/jochem#4250298", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4250298"
    ], 
    "type": "factoid", 
    "id": "56c3184050c68dd416000003", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 374, 
            "text": "These are the preliminary data of an open multicenter trial of antihypertensive treatment with isradipine as monotherapy (dose, 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0.63 mg twice daily) in combination with bopindolol (1.16 +/- 0.12 mg once daily; n = 30) administered for 3 years to patients with essential hypertension (WHO classification I or II). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/7946181", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 977, 
            "offsetInEndSection": 1138, 
            "text": " It is concluded that isradipine is safe and effective when administered long-term in the treatment of hypertensive patients with either hyperlipidemia or NIDDM.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/7946181", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 84, 
            "text": "Regression of left ventricular hypertrophy with isradipine antihypertensive therapy.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/8466736", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1584, 
            "offsetInEndSection": 1827, 
            "text": "Isradipine monotherapy was an effective antihypertensive drug in blacks with essential hypertension, resulting in regression of left ventricular wall thickness and mass and augmentation of fractional shortening per 100 g left ventricular mass.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/2137344", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 373, 
            "text": "These are the preliminary data of an open multicenter trial of antihypertensive treatment with isradipine as monotherapy (dose, 4.55 +/- 0.56 mg twice daily; n = 11) or isradipine (7.5 +/- 0.63 mg twice daily) in combination with bopindolol (1.16 +/- 0.12 mg once daily; n = 30) administered for 3 years to patients with essential hypertension (WHO classification I or II).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/7946181", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 184, 
            "text": "The antihypertensive effect of isradipine was studied in 45 patients with mild-to-moderate hypertension (mean age 59 years) using casual and ambulatory 24-h blood pressure measurement.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/8205296", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 48, 
            "offsetInEndSection": 84, 
            "text": "isradipine antihypertensive therapy.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/8466736", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 775, 
            "offsetInEndSection": 810, 
            "text": "isradipine antihypertensive therapy", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/8466736", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1584, 
            "offsetInEndSection": 1646, 
            "text": "Isradipine monotherapy was an effective antihypertensive drug ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/2137344", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 671, 
            "offsetInEndSection": 912, 
            "text": "Isradipine is cytoprotective after a stroke when used as an antihypertensive: at doses which normalise high blood pressure in spontaneously hypertensive rats, isradipine reduces by more than 60% the infarct size caused by a subsequent stroke", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/2150641", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 155, 
            "text": "[Long-term antihypertensive therapy with isradipine. Improvement of coronary flow reserve in patients with arterial hypertension and microvascular angina].", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/7848351", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 63, 
            "text": "[Isradipine in arterial hypertension in motor vehicle drivers].", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/8963604", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 101, 
            "text": "Evaluation of the safety and efficacy of isradipine in elderly patients with essential hypertension. ", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/2523644", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 113, 
            "text": "A multicenter evaluation of the safety and efficacy of isradipine and atenolol in the treatment of hypertension. ", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/2523646", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1255, 
            "offsetInEndSection": 1367, 
            "text": "it is advisable to be very careful in the use of isradipine as a therapy for hypertension and other indications.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15257873", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 182, 
            "text": "Calcium channel antagonists (CCAs) may either be divided into the dihydropyridines (e.g. amlodipine, felodipine, isradipine, lacidipine, nilvadipine, nifedipine, nicardipine etc.), t", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/14727944", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 195, 
            "offsetInEndSection": 374, 
            "text": "In the past few years, however, several dihydropyridine calcium channel antagonists, including nicardipine, isradipine, felodipine, nimodipine, and amlodipine, have been marketed.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/8213473", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 118, 
            "text": "The new calcium antagonist isradipine. Effect on blood pressure and the left ventricle in black hypertensive patients.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/2137344", 
            "endSection": "title"
        }
    ]
}